Navigation Links
Neurocrine Biosciences Reports Second Quarter 2011 Results
Date:7/28/2011

General and administrative expenses were $2.8 million for the second quarter of 2011 and $3.1 million during the same period last year. For the six months ended June 30, 2011, general and administrative expenses were $6.0 million, compared to $6.3 million for the first half of 2010. The decrease in general and administrative expenses is primarily due to lower facility related costs.

Other income increased to $0.9 million during the second quarter of 2011 from $0.7 million of income for the second quarter of 2010. Other income decreased from $2.3 million of income during the first half of 2010 to $1.8 million of income for the first half of 2011. The decrease in year-to-date other income resulted from a $0.5 million realized gain on the sale of auction rate securities in the first quarter of 2010.

Pipeline HighlightsElagolix UpdateElagolix Phase III trials for endometriosis are planned to start in the fourth quarter of 2011, with Phase II trials assessing elagolix in uterine fibroids expected to start in the third quarter of 2011.

Additionally, multiple abstracts and datasets from the development program of elagolix for endometriosis will be presented at the 2011 World Congress on Endometriosis to be held September 4-7, 2011 in Montpellier, France.

VMAT2 UpdateThe Company's VMAT2 inhibitor, NBI-98854, successfully completed two Phase I safety studies in healthy male volunteers and a Phase IIa study in tardive dyskinesia patients. Based on these three Canadian studies, the Company filed an Investigational New Drug Application with the FDA Division of Psychiatry.

A second Phase II study is expected to be initiated in the United States in September of this year to further assess NBI-98854 in tardive dyskinesia patients. The design of this Phase II study is a randomized, double-blind, placebo controlled, cross-over trial, using a within-subject comparison for safety and efficacy evaluation. This 32 patient study will as
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
2. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
3. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
4. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
5. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
6. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
7. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
8. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
10. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
11. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Quorum Review IRB, the industry leader in central ... called Quick Step™ . The offering went live on ... industry’s need for seamless study start-up with a large volume ... planning 50 or more North American investigator sites, as well ... count of 80 or more. Qualifying studies may also enroll ...
(Date:7/22/2014)... Angeles, CA (PRWEB) July 22, 2014 ... test solutions with the debut of its fluorescent ... of Clinical Chemistry (AACC) meeting in Chicago, July ... or bench top versions, the HRDR-300 is a ... pending technology to analyze fluorescent lateral flow immunoassays ...
(Date:7/22/2014)... Lawrence, KS (PRWEB) July 22, 2014 ... as attention-deficit hyperactivity disorder (ADHD) is diagnosed, selecting medication ... trial and error. Analyzing brain patterns by using electroencephalography ... best result and thus lower the risk of adverse ... Electroencephalography Phenotypes and Biomarkers” in the current issue ...
(Date:7/22/2014)... SC (PRWEB) July 22, 2014 Dr. ... of those who have recognized that the greatest health ... and far too often needlessly deadly while trying to ... multitude of quasi-experts seeking to transform an enormous system ... , Dr. Williams, in his continuing series of Open ...
Breaking Biology Technology:Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 3Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2
... N.J., March 18 Medarex, Inc. (Nasdaq: MEDX ... the Needham & Company Cancer Therapeutics: Today & Tomorrow Conference ... The event will be webcast live and will be available ... www.medarex.com . An archived edition of the presentation will ...
... StartUpHire launched today as the job search engine dedicated ... backed companies. These are some of the most ... been difficult to identify. The StartUpHire website, ... be filtered by industry, geography, functional area, investor, and ...
... XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB ; TASE: ... ("EGMs") held earlier today.All of the resolutions at the ... of Mark Allouche, Dafna Cohen, Yaron Diament, David Grossman, ... appointed Chairman. Dafna Cohen and Yaron Diament were ...
Cached Biology Technology:StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies 2StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies 3Extraordinary General Meetings Statement -- XTL Also Announces Board and Management Changes 2
(Date:7/21/2014)... species, investigators have found that migration routes are under ... which is published in Ecology Letters , was ... of a bird and allow its long distance movement ... exhibited increased variability in their migratory routes: some used ... the same routes as one parental group on fall ...
(Date:7/21/2014)... for the evolution of life are now being developed ... an evolving system of species. Specifically, a recent model ... Finland in Joensuu accounts for species interactions with various ... an improvement on previous, simpler models, which apply random ... EPJ E demonstrate that the resulting replicator ecosystems ...
(Date:7/21/2014)... Women,s Hospital (BWH) have developed a scalable, next-generation platelet ... The work is a major biomedical advancement that will ... is published July 21, 2014 in Blood . ... of functional human platelets with virtually no disease transmission ... that may allow us meet the growing need for ...
Breaking Biology News(10 mins):Refined biological evolution model 2Scientists successfully generate human platelets using next-generation bioreactor 2
... Envisat and the Italian Space Agency,s COSMO-SkyMed, scientists have ... the 6.3 earthquake that shook the medieval town of ... Scientists from Italy,s Istituto per il Rilevamento Elettromagnetico dell, ... Vulcanologia (INGV) are studying Synthetic Aperture Radar (SAR) data ...
... into how the deadly Hendra virus spreads promises to ... the future. CSIRO Livestock Industries, scientists working at ... have made a major breakthrough in better understanding how ... humans. Funded by the Australian Biosecurity ...
... BioMed Central,s 3rd Annual Research Awards were announced at ... The event was attended by shortlisted authors, eminent researchers ... journalists. The Research Awards, now in their ... made universally accessible by open access publication. The Awards ...
Cached Biology News:Satellites show how Earth moved during Italy quake 2Minimizing the spread of deadly Hendra virus 2Open access research celebrated 2
Human sVCAM-1/CD106 ELI-PAIR Kit...
GLP-1 (HYB 147-12)...
... Custom Synthesis Service provides you ... to knockdown any gene. We ... base pairs with terminal dT ... other lengths of your choice. ...
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
Biology Products: